AbbVie, Obesity and Licensing Deal

AbbVie Joins Obesity Treatment Market With Up to $2.2B Licensing Deal
Key Takeaways AbbVie agreed to license a weight-loss drug in development from Danish biotech firm Gubra.AbbVie said it will pay up to about $2.2 billion for the drug GUBamy, which is currently in a Phase 1 clinical trial.
AbbVie gets into obesity with $350M deal for once-weekly shot
A licensing deal with Denmark’s Gubra gives the immunology giant control of an experimental therapy that could compete with drugs from Novo Nordisk, Eli Lilly and Zealand.
AbbVie steps into the obesity drug race, licensing medicine from Danish firm
The obesity medicine field has gained a new entrant, with AbbVie licensing an experimental drug from a Danish company.
AbbVie enters obesity drug market with Danish drugmaker
AbbVie has signed a licensing deal with Gubra A/S to develop an obesity drug, marking the North Chicago company's first foray into the obesity market.
AbbVie, Gubra in Obesity-Drug License Pact Potentially Worth More Than $2 Billion
AbbVie is jumping into the burgeoning obesity field, striking a license agreement with Gubra that is potentially worth more than $2 billion to the Danish drug-discovery and contract-research-services company.
Obesity Late-Comer AbbVie Inks Up to $2.2B Amylin Deal With Gubra
AbbVie on Monday jumped into the hot weight-loss space, looking to gain ground on its Big Pharma peers, with a licensing deal with Danish company Gubra that aims to bring a long-acting amylin drug to the market.
Abbvie enters $2.2B deal for Gubra’s amylin obesity drug
Abbvie Inc. is buying into the obesity fray in a potential $1.875 billion development and commercialization agreement with Danish peptide drug discovery specialist Gubra A/S. In addition, there will be a $350 million up-front payment as Abbvie takes over the reins of GUB-014295 (referred to as Gubamy),
AbbVie pays Gubra $350M to make late play for obesity space
AbbVie is paying $350 million to join the obesity race. The outlay, plus up to $1.875 billion in milestones, has landed the drugmaker rights to a long-acting amylin analog that is in phase 1 development at Gubra.
AbbVie Enters Obesity Market Through Licensing Deal With Denmark's Gubra
AbbVie (ABBV) on Monday said it struck a licensing deal with Danish biotechnology company Gubra to develop a potential candidate for obesity treatment. AbbVie will be responsible for the global development and commercialization activities of GUB014295,
ABBV Enters Obesity Bandwagon, Inks $2.2B Licensing Deal for Amylin Drug
AbbVie ABBV announced that it has entered into a licensing agreement with Denmark-based biotech Gubra for the latter’s experimental obesity drug, GUB014295. This marks the American drugmaker’s foray into the lucrative obesity market.
AbbVie enters obesity space with $2.3bn Gubra deal
AbbVie is entering the obesity treatment market with a $2.3bn licensing agreement to acquire global rights to GUB014295, a long-acting amylin analogue developed by Danish biotech Gubra. Announced on 3 March,
Investor's Business Daily on MSN2d
AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion.
AbbVie inked a licensing deal Monday worth up to $2.23 billion for an amylin-targeting obesity treatment from Denmark-based ...
AbbVie Steps Into The Ring In The Obesity Drug Wars
AbbVie's strategic move into the obesity market through a partnership with Gubra A/S shows potential but won't impact revenue ...
STAT21h
How the race for the next obesity drug is shaping up
While some drugs have fallen off, more have been added: AbbVie recently jumped into the obesity craze by licensing an ...
MedCity News3d
AbbVie Enters Obesity Field, Paying $350M for Amylin Receptor Agonist Already in the Clinic
AbbVie is joining the chase for new obesity drugs, but rather than getting a me-too GLP-1 drug, the pharmaceutical giant is landing rights to a clinical-stage molecule that goes after two novel ...
AbbVie price target raised to $223 from $200 at BofA
BofA raised the firm’s price target on AbbVie (ABBV) to $223 from $200 and keeps a Neutral rating on the shares after the company and Gubra ...